

| 规格 | 价格 | 会员价 | 库存 | 数量 | |||
|---|---|---|---|---|---|---|---|
| {[ item.pr_size ]} |
{[ getRatePriceInt(item.pr_rmb, 1,1) ]} {[ getRatePriceInt(item.pr_rmb_sale, 1,1) ]} {[ suihuo_tips(item.pr_tag_price, item.pr_am) ]} |
{[ getRatePriceInt(item.pr_rmb, 1,1) ]} {[ getRatePriceInt(item.pr_rmb,item.pr_rate,1) ]} {[ suihuo_tips(item.pr_tag_price, item.pr_am) ]} |
{[ getRatePriceInt(item.pr_rmb, 1,1) ]}{[ suihuo_tips(item.pr_tag_price, item.pr_am) ]} | {[ getRatePrice(item.pr_rmb_sale, 1,1,item.mem_isinteger) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,item.mem_rate,item.mem_isinteger) ]} {[ getRatePrice(item.pr_rmb,1,item.mem_rate,item.mem_isinteger) ]} | 现货 | 1周 咨询 | - + |
快速发货 顺丰冷链运输,1-2 天到达
品质保证
技术支持
免费溶解

| 产品名称 | ALK ↓ ↑ | 其他靶点 | 纯度 | ||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASP3026 |
+
ALK, IC50: 3.5 nM |
99%+ | |||||||||||||||||
| ALK-IN-1 |
++++
ALK, IC50: 0.07 nM |
99% | |||||||||||||||||
| Crizotinib |
++++
ALK, IC50: 24 nM ROS1, Ki: <0.025 nM |
98% | |||||||||||||||||
| Entrectinib | ✔ | 99%+ | |||||||||||||||||
| Brigatinib |
+++
ALK, IC50: 0.37 nM ROS1, IC50: 1.9 nM |
FLT3 | 98% | ||||||||||||||||
| NVP-TAE 684 |
+
ALK, IC50: 3 nM |
99%+ | |||||||||||||||||
| Alectinib |
++
ALK (F1174L), IC50: 3.5 nM ALK, IC50: 1.9 nM |
98% | |||||||||||||||||
| Ceritinib |
+++
ALK, IC50: 0.2 nM |
Insulin Receptor,IGF-1R | 98% | ||||||||||||||||
| GSK1838705A |
+++
ALK, IC50: 0.5 nM |
Insulin Receptor,IGF-1R | 98% | ||||||||||||||||
| AZD-3463 |
++
ALK, Ki: 0.75 nM |
IGF-1R | 99% | ||||||||||||||||
| Lorlatinib |
++++
ALK (L1196M), Ki: 0.07 nM ROS1, Ki: <0.07 nM |
98% | |||||||||||||||||
| Repotrectinib |
+
ALK(L1196M), IC50: 1.01 nM ALK(G1202R), IC50: 1.26 nM |
Src | 99% | ||||||||||||||||
| Belizatinib |
++
ALK, IC50: 0.7 nM |
99%+ | |||||||||||||||||
| 1. 鼠标悬停在“+”上可以显示相关IC50的具体数值。"+"越多,抑制作用越强。2. "✔"表示该化合物对相应的亚型有抑制作用,但抑制强度暂时没有相关数据。 | |||||||||||||||||||
| 靶点 |
|
| 描述 | ALK (anaplastic lymphoma kinase) is a tyrosine kinase that is constitutively activated in certain cancers, following gene alterations such as chromosomal translocation, amplification or point mutation. The fusion protein NPM-ALK, which is generated from a hybrid gene consisting of the intracellular domain of the ALK tyrosine kinase receptor juxtaposed with nucleophosmin, has constitutive tyrosine kinase activity and is associated with 50–60% of cases of anaplastic large-cell lymphomas. NVP-TAE 684 is a potent and selective NPM-ALK kinase inhibitor without exhibiting significant cross-reactivity against other kinases tested, including the highly homologous InsR. Consistent with this, NVP-TAE 684 exhibited inhibitory concentrations (IC50) between 2 and 5nM in NPM-ALK-dependent cells, Ba/F3 NPM-ALK, SU-DHL-1 and Karpas-299, but not the parent Ba/F3-WT cells, with a dose-dependent reduction of NPM-ALK auto-phosphorylation. Through the inhibition of NPM-ALK kinase activity, the downstream signaling events, pSTAT3-Y705 and pSTAT5-Y694, were inhibited in a concentration- (>50nM) and time (50nM, >15min)-dependent manner in Ba/F3 NPM-ALK and Karpas-299 cells. Also, NVP-TAE 684 (>50nM) can lead a dose-dependent reduction in phosphorylation of both ERK and Akt in Karpas-299 cells after 4h of treatment. The G1 phase arrest and apoptosis induced by treatment with 50nM NVP-TAE 684 for 48h can be observed in NPM-ALK-expressing Ba/F3 cells and ALCL patient cell lines. Oral administration of NVP-TAE 684 at dose of 3 and 10mg/kg once daily for 4 weeks significantly delayed lymphoma development in Karpas-299 xenograft mice. Daily oral administration of NVP-TAE 684 at dose of 5 or 10mg/kg for 2 weeks initiated 12 days after Karpas-299 inoculation induced disease regression in mice. Reduction of p-ALK and p-STAT3, as well as CD30 expression (present as the ALCLs) can be observed at day 3 after dose[1]. |
| 作用机制 | NVP-TAE 684 is expected to bind with the ATP-binding site of ALK.[1] |
| Concentration | Treated Time | Description | References | |
| CLB-GA cell line | 300 nM | 6 h | Inhibition of ALK activity, leading to decreased RET mRNA levels | Oncogene. 2018 Mar;37(11):1417-1429. |
| CLB-MA cell line | 300 nM | 6 h | Inhibition of ALK activity, leading to decreased RET mRNA levels | Oncogene. 2018 Mar;37(11):1417-1429. |
| H3122 cells | 100nM | 6 h | To evaluate the effect of ALK inhibitor on PI3K signaling | Cancer Res. 2011 Sep 15;71(18):5965-75. |
| NB1 cells | 50 nM | 1 h | Completely suppressed LPA-induced ERK1/2 phosphorylation | Biomolecules. 2024 May 28;14(6):631. |
| Caki-1 cells | 3nM | 1 day | Inhibited RRM2 protein expression and reduced cell viability | EBioMedicine. 2022 Apr;78:103963. |
| LAN-1 cells | 50 nM | 1 h | Inhibited LPA-induced ERK1/2 phosphorylation | Biomolecules. 2024 May 28;14(6):631. |
| Kelly cells | 50 nM | 1 h | Inhibited LPA-induced ERK1/2 phosphorylation | Biomolecules. 2024 May 28;14(6):631. |
| SH-SY5Y cells | 50 nM | 1 h | Inhibited LPA-induced ERK1/2 phosphorylation and cell proliferation | Biomolecules. 2024 May 28;14(6):631. |
| CLB-GE cell line | 300 nM | 6 h | Inhibition of ALK activity, leading to decreased RET mRNA levels | Oncogene. 2018 Mar;37(11):1417-1429. |
| HCO1-GICs | 0.75 μM | 72 h | Inhibits ALK receptor and reduces self-renewal capacity of GICs | Theranostics. 2020 Apr 6;10(11):5120-5136. |
| 12O12-GICs | 0.75 μM | 72 h | Inhibits ALK receptor and reduces self-renewal capacity of GICs | Theranostics. 2020 Apr 6;10(11):5120-5136. |
| BE(2)C cells | 50 nM | 1 h | Completely suppressed LPA-induced ERK1/2 phosphorylation | Biomolecules. 2024 May 28;14(6):631. |
| GH2-GICs | 0.75 μM | 24 h | Inhibits ALK receptor, reduces SOX9 protein levels, and decreases self-renewal capacity of GICs | Theranostics. 2020 Apr 6;10(11):5120-5136. |
| KB-CV60 cells | 0.2 µM and 0.5 µM | 72 h | To evaluate the reversal effect of NVP-TAE684 on ABCC1-mediated multidrug resistance. Results showed that NVP-TAE684 did not significantly reverse ABCC1-mediated resistance. | Front Oncol. 2020 Feb 27;10:228. |
| HEK293/ABCG2 cells | 0.2 µM and 0.5 µM | 72 h | To evaluate the reversal effect of NVP-TAE684 on ABCG2-transfected cells. Results showed that NVP-TAE684 significantly decreased the resistance in ABCG2-transfected cells. | Front Oncol. 2020 Feb 27;10:228. |
| NCI-H460/MX20 cells | 0.2 µM and 0.5 µM | 72 h | To evaluate the reversal effect of NVP-TAE684 on ABCG2-mediated multidrug resistance. Results showed that NVP-TAE684 significantly decreased the resistance in ABCG2-overexpressing cells. | Front Oncol. 2020 Feb 27;10:228. |
| SK-N-BE(2)C cell line | 300 nM | 6 h | Inhibition of ALK activity, leading to a slight decrease in RET mRNA levels | Oncogene. 2018 Mar;37(11):1417-1429. |
| Neuroblastoma cells (LS cells) | 1 μM | 24 h | Inhibition of ALK activity, reduction of pY-GSK3 expression, affecting cell migration | Nat Commun. 2018 Mar 19;9(1):1126. |
| Neuroblastoma cells (Kelly cells) | 1 μM | 24 h | Inhibition of ALK activity, reduction of pY-GSK3 expression, affecting cell migration | Nat Commun. 2018 Mar 19;9(1):1126. |
| Administration | Dosage | Frequency | Description | References | ||
| Mice | Cocaine sensitization and conditioned place preference model | Oral gavage | 10 mg/kg | Once daily for 7 days | To evaluate the effect of TAE684 on cocaine-induced behavioral responses, results showed TAE684 delayed cocaine sensitization and reduced conditioned place preference | J Neurosci. 2011 Oct 5;31(40):14134-41 |
| Nude mice | H3122 lung cancer xenograft model | Orogastric gavage | 25 mg/kg/d | Once daily for 2 days | To evaluate the effect of TAE-684 on tumor growth and PI3K signaling | Cancer Res. 2011 Sep 15;71(18):5965-75. |
| Dose | Mice: 1 mg/kg - 20 mg/kg[1] (p.o.), 0.5 mg/kg[2] (p.o.) | ||||||||||||
| Administration | p.o. | ||||||||||||
| Pharmacokinetics |
|
| 计算器 | ||||
| 存储液制备 | ![]() |
1mg | 5mg | 10mg |
|
1 mM 5 mM 10 mM |
1.63mL 0.33mL 0.16mL |
8.14mL 1.63mL 0.81mL |
16.28mL 3.26mL 1.63mL |
|
| CAS号 | 761439-42-3 |
| 分子式 | C30H40ClN7O3S |
| 分子量 | 614.2 |
| SMILES Code | CN1CCN(C2CCN(C3=CC=C(NC4=NC=C(Cl)C(NC5=CC=CC=C5S(=O)(C(C)C)=O)=N4)C(OC)=C3)CC2)CC1 |
| MDL No. | MFCD11977634 |
| 别名 | TAE 684 |
| 运输 | 蓝冰 |
| InChI Key | QQWUGDVOUVUTOY-UHFFFAOYSA-N |
| Pubchem ID | 16038120 |
| 存储条件 |
In solvent -20°C: 3-6个月 -80°C: 12个月 Pure form Keep in dark place, inert atmosphere, store in freezer, under -20°C |
| 溶解方案 |
DMSO: 6 mg/mL(9.77 mM),配合低频超声助溶,注意:DMSO长时间开封后,会吸水并导致溶解能力下降,请避免使用长期开封的DMSO 以下溶解方案都请先按照体外实验的方式配制澄清的储备液,再依次添加助溶剂: ——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议现用现配,当天使用; 以下溶剂前显示的百分比是指该溶剂在终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶
|
沪公网安备 31011702889066号
沪ICP备2024050318号-1